Meeting Minutes: Drug Formulary Committee

Date & Time: May 17, 2017, 5-9PM
Minutes prepared by: Dave Hoang
Location: Elmer Andersen Building, Room 2340, 540 Cedar Street, St. Paul, MN  55101

Attendance

• Members in attendance: Al Heaton, RPh, Kathryn Lombardo, M.D., Kelly Ruby, Pharm.D., Margaret Artz, RPh, Ph.D., Michael Sprehe, M.D., Monica Brands, R.Ph., Stacey Ness, Pharm.D, Kyle Lehenbauer, MD, Eric Meininger, MD, MPH.
• The committee welcome its new member, Dr. Kyle Lehenbauer, MD. Dr. Lehenbauer works at the VA Medical Center in Minneapolis
• Members absent: James Phillips, M.D., Stuart Williams, J.D.
• DHS staff present: Chad Hope, PharmD, Jeff Schiff, MD, MBA, Dave Hoang, Pharm.D., MBA, MBA, Mary Beth Reinke, PharmD, MSA.
• Others in attendance: Nina Bandali, Pharm.D., Ariane Casey, Pharm.D.

Report of the Chair

No updates

Approval of Minutes

Minutes from the August 2016 meeting was reviewed and approved

Class Review: New Specialty Drugs for Continued PA

• The committee discussed Adlyxin and recommended to the department by a unanimous vote that Adlyxin remain on PA. The committee also recommended that the PA criteria for the GLP-1 receptor agonist class contain denial criteria that is consistent for all agents within this class
• The committee discussed Soliqua and Xultophy and recommended to the department by a unanimous vote that Soliqua and Xultophy remain on PA. The committee also recommended that the PA criteria for basal insulin and GLP-1 receptor agonist combination contain additional step therapies to make it consistent with the PA criteria for GLP-1 receptor agonist class
New Specialty Drugs for Continued PA

- The committee discussed Exondys-51 and recommended to the department by a unanimous vote that Exondys-51 remain on PA. The committee also recommended that the PA criteria requires provider’s attestation rather than chart documentation for some of the PA criteria.
- The committee discussed Lartruvo and recommended to the department by a unanimous vote that Lartruvo remain on PA. The committee also recommended that PA requires provider’s attestation rather than chart documentation on reproductive health counseling.
- The committee discussed Basaglar and recommended to the department by a majority vote that Basaglar remain on PA. One committee member dissented. DHS Clinical Pharmacist proposed to have a short presentation on biosimilars overview at a future DFC meeting.
- The committee discussed Zinplava and recommended to the department by a unanimous vote that Zinplava remain on PA.
- The committee discussed Spinraza and recommended to the department by a unanimous vote that Spinraza remain on PA.
- The committee discussed Rubraca and recommended to the department by a unanimous vote that Rubraca remain on PA. The committee also recommended that PA requires provider’s attestation rather than chart documentation on reproductive health counseling.

New Drugs for Continued PA

- The committee discussed Vemlidy and recommended to the department by a unanimous vote that Vemlidy remain on PA. The committee also recommended specific monitoring criteria be added to the renewal approval criteria.
- The committee discussed Rayaldee and recommended to the department by a unanimous vote that Rayaldee remain on PA.
- The committee discussed Eucrisa and recommended to the department by a unanimous vote that Eucrisa remain on PA.

Existing Specialty Drugs for Continued PA

- The committee discussed Authorized Generic (AG) of Adrenaclick and recommended to the department by a unanimous vote that AG of Adrenaclick remain on PA. The committee also discussed the epinephrine auto-injectors therapeutic class and recommended to the department the class be managed based on cost.
Adjournment

- The meeting was adjourned at 9:20PM Central Time